Stay Tuned: ASCO 2010 is Just Around the Corner

Article

The theme of this year’s ASCO meeting is “advancing quality through innovation.” As always, the vast scope of this annual meeting is daunting. In order to give our readers an ongoing analysis of ASCO ’10, The Oncology Forum will be posting daily from Chicago, parsing out the best sessions and most relevant clinical information.

The theme of this year’s annual  ASCO meeting is “advancing quality through innovation.” As always, the vast scope of this international meeting is daunting. In order to give our readers an ongoing analysis of ASCO ’10, The Oncology Forum will be posting daily from Chicago, parsing out the best sessions and most relevant clinical information. 

The Forum will also highlight the most important practice management information, nuts & bolts tips that will help your practice’s bottom line and analysis of how Obama’s healthcare bill will impact the ability to treat your patients in the brave new world of comparative effectiveness research (CER) and steep Medicare cuts.


Here’s a new feature from this year’s meeting:

Trials in Progress Poster Session
 

The new Trials in Progress Poster Session will facilitate awareness of and dialogue about open, ongoing clinical trials. It differs from other Poster Sessions in that:

--outcomes data or results are not included,

--the goal is to promote discussion among trial investigators, to encourage recruitment of new investigators or sites, and to stimulate discussion of successor or confirmatory trials, 

--the focus is on the background of the science behind the trial, and preclinical or earlier-phase data (preferably with references) is encouraged.
 

Also, watch The Forum for exclusive interviews from the meeting's top presenters.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content